Enlivex Therapeutics Business Summary

Enlivex Therapeutics Ltd. (ENLV) is a clinical-stage immunotherapy company utilizing a dual-engine business model that combines macrophage reprogramming drug development with a novel digital asset treasury strategy. The company generates value through its lead candidate, Allocetra™, an off-the-shelf cell therapy designed to restore immune balance in life-threatening inflammatory conditions, with a primary commercial focus on the multi-billion-dollar knee osteoarthritis (KOA) market. Following a transformative $212 million private placement in late 2025, Enlivex also operates a digital asset treasury segment centered on the RAIN protocol, a decentralized prediction markets platform, to generate yield and capital appreciation intended to fund clinical operations and minimize equity dilution. Within the competitive landscape of innate immunity and cell therapy, Enlivex competes with firms such as Agenus, BioNTech, Kymera Therapeutics, and Kamada, distinguishing itself as a first-mover in macrophage-targeted treatments for osteoarthritis and the first NASDAQ-listed entity to integrate a prediction-market-based treasury reserve. The leadership team is anchored by Executive Chairman and Co-Founder Shai Novik and CEO Dr. Oren Hershkovitz, both of whom previously held senior roles at PROLOR Biotech (acquired by OPKO Health). The company’s scientific foundation is led by Co-Founder and Scientific Adviser Prof. Dror Mevorach, a global authority on apoptotic cell clearance and macrophage homeostasis. Other key executives include CFO Shachar Shlosberger and Vice Chairman Dr. Roger Pomerantz, the former CEO of Seres Therapeutics and a former senior executive at Merck & Co. Enlivex maintains a high-profile board of directors, which notably includes former Italian Prime Minister Matteo Renzi, appointed in November 2025 to oversee the company’s strategic expansion. The firm is backed by prominent institutional investors, including Pontifax, Korea Investment Holdings, and Hadasit, providing a robust capital base for its upcoming Phase IIb clinical trials scheduled for mid-2026.